All News

Study suggests future interventions targeting improvements in cancer screenings may need to focus on the time of day when a patient visits a doctor.

The study focused on the comparative risk of infection across 7 systemic biologics.

Top news of the day from across the health care landscape.

Why is a woman's health declining, and she's turning yellow?

Parvus Therapeutics and Genentech have entered into a worldwide collaboration and licensing agreement for the development, manufacturing, and commercialization of treatments for inflammatory bowel disease, autoimmune liver diseases, and celiac disease using nanomedicines (Navacim) developed by Parvus.

Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, recently explored both sides of the debate as to whether these tools are effective for managing costs or add barriers to patient access.

Officials with the FDA have approved extending the indication of Takeda Pharmaceuticals’ teduglutide (Gattex) for injection to pediatric patients age 1 year and older with Short Bowel Syndrome who need additional nutrition or fluids from intravenous feeding.

A goal of SBS treatment is to restore the patient’s ability to absorb nutrients and reduce long-term dependence on parenteral support.

The convenience of home infusion for these products is very enticing for patients who require them and positioning home infusion pharmacies as partners with prescribers and patients is critical to help support this influx of new therapies.

Top news of the day from across the health care landscape.

The final rule requires Part D plans to adopt tools that provide clinicians with information that they can discuss with patients on out-of-pocket costs for prescription drugs at the time a prescription is written.

Dalteparin sodium is the first anticoagulant indicated for pediatric patients approved by the agency.

VTE can include deep vein thrombosis and pulmonary embolism, which can lead to death.

When both of these compounds are in abundant supply, good things happen.

An analysis showed short-term health plans can expose enrollees to significant out-of-pocket costs for serious illnesses, such as cancer.

Study explored a novel drug’s efficacy in overcoming ibrutinib-resistant mantle cell lymphoma.

Top news of the day from across the health care landscape.

The annual KANTAR Readership Study encompasses readership habits of thousands of pharmacists and pharmacy professionals, working in the areas of chain, independent retail pharmacies and health-system pharmacies.

Civica has made plans to deliver 14 essential generic medications this year.

The combination therapy received Breakthrough Therapy designation in March 2019 for previously-untreated CLL.

The approval of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) offers an additional option for adults with previously-untreated chronic lymphocytic leukemia.

This report revealed that in 2016, an estimated 3900 of 4200 or 93% incident HIV infections among black women would not have occurred if the incidence for black women were the same as that for white women.

This first-to-market point-of-sale platform combines industry expertise, artificial intelligence and comprehensive, deep-data libraries to seek out and identify errors so that the right discounts are applied to the right transaction.

The FDA’s Oncology Drugs Advisory Committee challenged the results of the phase 3 QuANTUM-R study.

Avelumab (Bavencio) plus axitinib (Inlyta) is indicated for the first-line treatment of patients with advanced renal cell carcinoma.

Top news of the day from across the health care landscape.

Risdiplam showed continued improvements in motor milestones and functions for patients with spinal muscular atrophy.

This is the first FDA approval for an anti-PD-L1 therapy as part of a combination regimen for patients with advanced RCC, according to EMD Serono.